DadFinStart your free week
DadFin › Stocks › Healthcare › SCYX

SCYNEXIS, Inc. (SCYX) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · United States

$4.08 ▼ -3.32% today

62.1
Dad Score, out of 100
middling

SCYNEXIS, Inc. (SCYX) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 62.1 out of 100 on the Dad Score, a middling reading that places the business ahead of 62% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #324 of 974. Its strongest axes are price action, risk and liquidity; its weakest are valuation and quality.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Weak
Quality
Below average
Growth
Average
Price action
Strong
Risk
Above average
Conviction
Below average
Liquidity
Strong
Macro
Above average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)-2.2×
Dividend yield0.00%
Return on capital-15.8%
Operating margin-3308.5%
Revenue growth (YoY)+450.0%
FCF yield-17.8%
Net debt / EBITDA3.00×
Piotroski F-Score4 / 9
52-week change-18.8%
Market cap$51M
Next earningsNov 4, 2026

What subscribers see on SCYX

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TAKTakeda Pharmaceutical Company Limi32.9weak$57.1B
TEVATeva Pharmaceutical Industries Lim93.6strong$46.1B
HLNHaleon plc64.5middling$38.7B
ZTSZoetis Inc.61.2middling$28.8B
UTHRUnited Therapeutics Corporation99.8strong$23.2B
VTRSViatris Inc.54.4middling$20.2B
NBIXNeurocrine Biosciences, Inc.98.4strong$14.6B
ELANElanco Animal Health Incorporated84.0good$11.1B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.